This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -80% and 4.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
SNDL INC (SNDL) delivered earnings and revenue surprises of 33.33% and 4.79%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -83.33% and 0.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OrganiGram (OGI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -66.67% and 10.57%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Evolus (EOLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
by Zacks Equity Research
Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -137.50% and 2.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Evolus (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -75% and 2.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Evolus (EOLS) Releases Favorable Dermal Fillers Study Data
by Zacks Equity Research
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evolus (EOLS) delivered earnings and revenue surprises of -85.71% and 0.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
Green Thumb Industries Inc. (GTBIF) Surges 22.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
3 Top Stocks to Invest in for Amazing Earnings Acceleration
by Tirthankar Chakraborty
Invest in companies such as Zymeworks (ZYME), Evolus (EOLS) and Bilibili (BILI) for superb earnings acceleration.
4 Stocks to Buy for Attractive Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 63.2% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 25% and 9.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 133.9% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.